Switzerland· 67660002
Balversa
A erdafitinib product containing erdafitinibum, registered in Switzerland and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 14 of our 19 countries.
Checked against BAG Spezialitätenliste (Switzerland) on
Informational only — not a medical device.
Where it is registered
Erdafitinib is registered in 14 of 19 countries.
Countries holding a registration under ATC L01EN01 (erdafitinib), each read from that country’s own register.
- This record: Switzerland, from BAG Spezialitätenliste (Switzerland)
- 8 of them publish a price we can compare per daily dose
Erdafitinib · ATC L01EN01
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of erdafitinib costs, country by country.
Normalised to the WHO defined daily dose (9 mg), the median price runs from $0.55 in France to $621.10 in Switzerland — a ×1128 gap.
- Switzerland: $621.10 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Erdafitinib · price per daily dose (9 mg)
USD · FX 28 Sept 2026
- CH Switzerland$621.10
- FR France$0.55
The record
At a glance
BAG Spezialitätenliste (Switzerland)- Active substance
- erdafitinibum
- Manufacturer
- —
- Country
- Switzerland (CH)
- ATC code
- L01EN01
- ATC class
- Erdafitinib
- Defined daily dose
- 9 mg, O
- Swissmedic category
- A
- Reimbursed
- Yes
- Source register
- BAG Spezialitätenliste (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin7680676600020Ds 84 StkCHF 9209.2
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
154 interactions on record for erdafitinib.
Graded by severity as the source publishes them — 56 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Erdafitinib · interactions on record
154 records
- 56 severe
- 98 moderate
Most severe, free to view
- Magnesium carbonateA02AA01severe
- Magnesium oxideA02AA02severe
- Magnesium hydroxideA02AA04severe
- Kombinationen von AluminiumsalzenA02AB10severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Erdafitinib in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaBALVERSAJanssen-Cilag International N.V., Beerse
- SpainBALVERSA 3 MG COMPRIMIDOS RECUBIERTOS CON PELICULAJanssen-Cilag International N.V
- FinlandBalversaJanssen Cilag International
- FranceBALVERSA 3 mg, comprimés pelliculésJANSSEN CILAG INTERNATIONAL NV
- IrelandBalversa 3 mg Film-coated tabletJanssen-Cilag International NV
- IcelandBalversaJanssen-Cilag International NV*
- NetherlandsBalversa 3 mg filmomhulde tablettenJanssen-Cilag International NV
- NorwayBalversaJanssen-Cilag International N.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Balversa
- Liechtenstein · Balversa
- Norway · Balversa
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of BAG Spezialitätenliste (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/6a3d9fc9-2180-40b3-9a7b-95ac2f9ad2f8 GET /v1/drugs/6a3d9fc9-2180-40b3-9a7b-95ac2f9ad2f8?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "erdafitinibum 3 mg",
"valid_from": "2025-07-01",
"limitations": "[{\"description\":\"Nach Kostengutsprache durch den Krankenversicherer nach vorgängiger Konsultation des Vertrauensarztes.<br>\\n<br>\\nBALVERSA als Monotherapie wird vergütet für die Behandlung erwachsener Patienten mit nicht resezierbarem oder metastasiertem Urothelkarzinom (mUC) mit FGFR3-Alteration, bei denen die Erkrankung nach einem PD-(L)1-Inhibitor (Programmed Death Receptor-1- bzw. Programmed Death-Ligand 1-Inhibitor) fortgeschritten ist, sowie nach einer platinhaltigen Chemotherapie, wenn diese dafür geeignet sind. Nicht mehr als zwei vorherige systemische Behandlungen.<br>\\n<br>\\nDie Behandlung von BALVERSA erfolgt bis zur Progression der Erkrankung oder dem Auftreten inakzeptabler Toxizität. Falls es unter BALVERSA-Therapie zu einer Progression kam, soll BALVERSA in derselben Indikation in nachfolgenden Therapielinien nicht mehr vergütet werden.<br>\\n<br>\\nDie Zulassungsinhaberin erstattet dem Krankenversicherer, bei dem die versicherte Person zum Zeitpunkt des Bezugs versichert war, auf dessen erste Aufforderung hin für jede bezogenen Packung BALVERSA einen festgeschriebenen Anteil des FAP zurück.<br>\\nDie Zulassungsinhaberin gibt dem Krankenversicherer die Höhe der Rückvergütung bekannt. Die Mehrwertsteuer kann nicht zusätzlich zu diesem Anteil des Fabrikabgabepreises zurückgefordert werden. Die Aufforderung zur Rückvergütung soll ab dem Zeitpunkt der Verabreichung erfolgen.<br>\\n<br>\\nFolgender Code ist an den Krankenversicherer zu übermitteln: 21854.01<br>\\n<br>\",\"costApproval\":null,\"indication\":\"21854.01\",\"isNew\":false,\"limitationCode\":null,\"points\":null,\"priceModel\":null,\"title\":null,\"validFrom\":\"2025-07-01\",\"validTo\":\"2028-06-30\"}]",
"galenic_form": "Filmtabl 3 mg",
"therapeutic_area": null,
"sl_inclusion_date": "2025-07-01",
"self_retention_pct": 10
}See everything about erdafitinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.